Emergent Biosolutions
EBS
163 hedge funds and large institutions have $637M invested in Emergent Biosolutions in 2014 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 57 increasing their positions, 58 reducing their positions, and 14 closing their positions.
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
2% more funds holding
Funds holding: 160 → 163 (+3)
1.71% more ownership
Funds ownership: 77.92% → 79.63% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 58
3% less capital invested
Capital invested by funds: $655M → $637M (-$18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FMA
Fiduciary Management Associates
Chicago,
Illinois
|
+$14.9M |
| 2 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$9.07M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.64M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$6M |
| 5 |
CM
Castleark Management
Chicago,
Illinois
|
+$4.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$14.3M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$5.33M |
| 3 |
GAM
Gotham Asset Management
New York
|
-$4.99M |
| 4 |
Morgan Stanley
New York
|
-$3.44M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.82M |
EBS Hedge Fund Activity: Q3 2014 in Review
163 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2014, worth a combined $637M — down 2.8% from $655M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new EBS positions and 14 closed out — a net gain of 3 holders — while 57 added to existing stakes and 58 trimmed.
The largest buyer was Fiduciary Management Associates, opening a new position worth an estimated $14.9M. The largest seller was Numeric Investors, exiting entirely with an estimated $14.3M sold.
- 163 institutional investors held Emergent Biosolutions (EBS) as of Q3 2014, up from 160 in Q2 2014.
- Funds reported $637M of Emergent Biosolutions stock for Q3 2014, down 2.8% quarter-over-quarter.
- 17 funds opened new Emergent Biosolutions positions in Q3 2014 and 14 closed out, a net change of +3 holders.
- The largest Emergent Biosolutions buyer in Q3 2014 was Fiduciary Management Associates, an estimated $14.9M added.
- The largest Emergent Biosolutions seller in Q3 2014 was Numeric Investors, an estimated $14.3M sold.
Based on aggregated 13F filings for Q3 2014.